V1RH5 Inhibitors
V1RH5 inhibitors are a specialized class of chemical compounds designed to target and inhibit the activity of the V1RH5 protein. The V1RH5 protein is a component of the V1 domain of the V-ATPase (vacuolar-type H+-ATPase) complex, which is involved in acidifying intracellular compartments such as lysosomes, endosomes, and vacuoles. The V1RH5 protein plays a crucial role in the functionality of the V-ATPase by contributing to its structural integrity and its ability to pump protons across the membrane. Inhibitors of V1RH5 specifically interfere with this protein's role within the V-ATPase complex, thereby impacting the overall proton pump activity.
The mechanism of action of V1RH5 inhibitors involves binding to the V1RH5 protein and obstructing its function within the V-ATPase complex. This binding prevents the V1RH5 protein from performing its role in maintaining the structural and functional stability of the V-ATPase. As a result, the efficiency of proton transport is reduced, which affects the acidification of intracellular compartments. By inhibiting V1RH5, these compounds can disrupt the normal operation of the V-ATPase, leading to alterations in pH regulation and other cellular processes dependent on the acidic environment. Research into V1RH5 inhibitors provides insights into the specific functions of V1RH5 within the V-ATPase complex and helps elucidate the broader implications of V-ATPase activity in cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome, potentially leading to the degradation of transcription factors involved in V1R214 expression. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 inhibits the proteasome, potentially leading to the degradation of transcription factors involved in V1R214 expression. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib inhibits the proteasome, potentially leading to the degradation of transcription factors involved in V1R214 expression. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib inhibits the proteasome, potentially leading to the degradation of transcription factors involved in V1R214 expression. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin inhibits the proteasome, potentially leading to the degradation of transcription factors involved in V1R214 expression. | ||||||
Bcr-abl Inhibitor | 778270-11-4 | sc-203836 | 5 mg | $149.00 | 1 | |
GNF-2 is a proteasome inhibitor that may lead to the degradation of transcription factors involved in V1R214 expression. | ||||||
ONX 0914 | 960374-59-8 | sc-477437 | 5 mg | $245.00 | ||
ONX-0914 inhibits the proteasome, potentially leading to the degradation of transcription factors involved in V1R214 expression. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib inhibits the proteasome, potentially leading to the degradation of transcription factors involved in V1R214 expression. | ||||||